[go: up one dir, main page]

EA201001162A1 - Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf - Google Patents

Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf

Info

Publication number
EA201001162A1
EA201001162A1 EA201001162A EA201001162A EA201001162A1 EA 201001162 A1 EA201001162 A1 EA 201001162A1 EA 201001162 A EA201001162 A EA 201001162A EA 201001162 A EA201001162 A EA 201001162A EA 201001162 A1 EA201001162 A1 EA 201001162A1
Authority
EA
Eurasian Patent Office
Prior art keywords
csf
treatment
antagonist
disorders
reduction
Prior art date
Application number
EA201001162A
Other languages
English (en)
Inventor
Кристофер Р. Беббингтон
Джеффри Т. Яррантон
Original Assignee
Калобиос Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40673999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201001162(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Калобиос Фармасьютикалс, Инк. filed Critical Калобиос Фармасьютикалс, Инк.
Publication of EA201001162A1 publication Critical patent/EA201001162A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение основано на открытии, что антагонисты GM-CSF можно использовать для лечения расстройств с уменьшением костной массы, таких как остеопения. Соответственно, изобретение относится к способам введения антагониста GM-CSF, например антител к GM-CSF, пациенту, у которого имеется расстройство с уменьшением костной массы, и фармацевтическим композициям, включающим такие антагонисты.
EA201001162A 2008-01-15 2009-01-15 Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf EA201001162A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2121808P 2008-01-15 2008-01-15
PCT/US2009/031126 WO2009091905A1 (en) 2008-01-15 2009-01-15 Methods of treating bone-loss disorders using a gm-csf antagonist

Publications (1)

Publication Number Publication Date
EA201001162A1 true EA201001162A1 (ru) 2010-12-30

Family

ID=40673999

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001162A EA201001162A1 (ru) 2008-01-15 2009-01-15 Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf

Country Status (10)

Country Link
US (2) US20090181020A1 (ru)
EP (1) EP2245062B1 (ru)
JP (1) JP2011510015A (ru)
CN (1) CN101932603A (ru)
AT (1) ATE555131T1 (ru)
AU (1) AU2009206082A1 (ru)
BR (1) BRPI0907220A2 (ru)
CA (1) CA2711763A1 (ru)
EA (1) EA201001162A1 (ru)
WO (1) WO2009091905A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222846B1 (en) * 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2014138862A1 (en) * 2013-03-14 2014-09-18 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
MX369360B (es) 2013-03-20 2019-11-06 Baylor College Medicine ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CN107655871A (zh) * 2017-09-12 2018-02-02 重庆医科大学 一种阿仑膦酸钠的高灵敏宽检测范围荧光检测新方法
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
CN117126277B (zh) * 2023-10-26 2024-01-23 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5611394A (en) * 1992-11-19 1994-06-08 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法

Also Published As

Publication number Publication date
EP2245062A1 (en) 2010-11-03
US20090181020A1 (en) 2009-07-16
JP2011510015A (ja) 2011-03-31
EP2245062B1 (en) 2012-04-25
AU2009206082A1 (en) 2009-07-23
ATE555131T1 (de) 2012-05-15
CA2711763A1 (en) 2009-07-23
CN101932603A (zh) 2010-12-29
WO2009091905A1 (en) 2009-07-23
US20120009191A1 (en) 2012-01-12
BRPI0907220A2 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
EA201001162A1 (ru) Способы лечения расстройств с уменьшением костной массы с использованием антагониста gm-csf
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EA201590748A1 (ru) Противовирусные соединения против rsv
EA200870409A1 (ru) Антагонисты киназы pi3
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EA201170227A1 (ru) Имидазолкарбоксамиды
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
EA201170832A1 (ru) Пуриновые соединения
EA201270767A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
EA201071320A1 (ru) Активаторы глюкокиназы
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors